在一个多民族、中等收入的亚洲环境中,乳腺癌女性患者的发病、管理和生存趋势。

IF 3.2 Q2 ONCOLOGY JCO Global Oncology Pub Date : 2024-08-01 DOI:10.1200/GO.24.00054
Sharminii Jaya-Prakason, Yek-Ching Kong, Cheng-Har Yip, Mee-Hoong See, Nur Aishah Taib, Nur Fadhlina Abdul Satar, Suniza Jamaris, Li Ying Teoh, Rose Irnawaty Ibrahim, Nirmala Bhoo-Pathy
{"title":"在一个多民族、中等收入的亚洲环境中,乳腺癌女性患者的发病、管理和生存趋势。","authors":"Sharminii Jaya-Prakason, Yek-Ching Kong, Cheng-Har Yip, Mee-Hoong See, Nur Aishah Taib, Nur Fadhlina Abdul Satar, Suniza Jamaris, Li Ying Teoh, Rose Irnawaty Ibrahim, Nirmala Bhoo-Pathy","doi":"10.1200/GO.24.00054","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Granular data on breast cancer (BC) are pertinent for surveillance, planning, and monitoring of cancer care delivery. We determined the trends in clinical presentation, management, and survival of women with BC in a multiethnic middle-income Asian setting over 15 years.</p><p><strong>Methods: </strong>Data of 7,478 Malaysian women newly diagnosed with invasive BC between 2005 and 2019 from three hospital-based cancer registries were included. Trends in demographic, tumor, and treatment characteristics were compared across period 1 (P1): 2005-2009, period 2 (P2): 2010-2014, and period 3 (P3): 2015-2019. Overall survival and net survival were determined.</p><p><strong>Results: </strong>More women in P3 than P1 were older than 60 years at diagnosis. Only a marginal increase in proportion of women with stage I disease was observed (23.7% <i>v</i> 27.2% in P1 and P3, respectively, <i>P</i> = .004). Nonetheless, patients were increasingly presenting with smaller tumors, fewer axillary node involvement, well-differentiated tumors, and hormone receptor expression in recent times. Proportion of women with human epidermal growth factor receptor 2 (HER2)-overexpressed tumors significantly decreased. Among indicated patients, receipt of anticancer therapies was somewhat similar over the calendar periods, except for neoadjuvant chemotherapy and anti-HER2 therapy, where increases in administration were noted. Significant improvements in survival were observed over the 15 years, particularly for HER2-overexpressed BCs.</p><p><strong>Conclusion: </strong>Although the improvements in BC survival that we have observed validate ongoing cancer control efforts and treatment advances, study findings suggest that more could be done for earlier detection and improved access to effective therapies in our settings.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trends in Presentation, Management, and Survival of Women With Breast Cancer in a Multiethnic, Middle-Income Asian Setting.\",\"authors\":\"Sharminii Jaya-Prakason, Yek-Ching Kong, Cheng-Har Yip, Mee-Hoong See, Nur Aishah Taib, Nur Fadhlina Abdul Satar, Suniza Jamaris, Li Ying Teoh, Rose Irnawaty Ibrahim, Nirmala Bhoo-Pathy\",\"doi\":\"10.1200/GO.24.00054\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Granular data on breast cancer (BC) are pertinent for surveillance, planning, and monitoring of cancer care delivery. We determined the trends in clinical presentation, management, and survival of women with BC in a multiethnic middle-income Asian setting over 15 years.</p><p><strong>Methods: </strong>Data of 7,478 Malaysian women newly diagnosed with invasive BC between 2005 and 2019 from three hospital-based cancer registries were included. Trends in demographic, tumor, and treatment characteristics were compared across period 1 (P1): 2005-2009, period 2 (P2): 2010-2014, and period 3 (P3): 2015-2019. Overall survival and net survival were determined.</p><p><strong>Results: </strong>More women in P3 than P1 were older than 60 years at diagnosis. Only a marginal increase in proportion of women with stage I disease was observed (23.7% <i>v</i> 27.2% in P1 and P3, respectively, <i>P</i> = .004). Nonetheless, patients were increasingly presenting with smaller tumors, fewer axillary node involvement, well-differentiated tumors, and hormone receptor expression in recent times. Proportion of women with human epidermal growth factor receptor 2 (HER2)-overexpressed tumors significantly decreased. Among indicated patients, receipt of anticancer therapies was somewhat similar over the calendar periods, except for neoadjuvant chemotherapy and anti-HER2 therapy, where increases in administration were noted. Significant improvements in survival were observed over the 15 years, particularly for HER2-overexpressed BCs.</p><p><strong>Conclusion: </strong>Although the improvements in BC survival that we have observed validate ongoing cancer control efforts and treatment advances, study findings suggest that more could be done for earlier detection and improved access to effective therapies in our settings.</p>\",\"PeriodicalId\":14806,\"journal\":{\"name\":\"JCO Global Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO Global Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1200/GO.24.00054\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Global Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/GO.24.00054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:有关乳腺癌(BC)的详细数据对癌症护理服务的监测、规划和监控至关重要。我们确定了一个多民族中等收入亚洲环境中患乳腺癌妇女 15 年来的临床表现、管理和生存趋势:方法:纳入了 2005 年至 2019 年间新诊断为浸润性 BC 的 7478 名马来西亚妇女的数据,这些数据来自三个以医院为基础的癌症登记处。比较了第 1 期(P1)、第 2 期(P2)、第 3 期(P4)和第 4 期(P5)的人口统计、肿瘤和治疗特征趋势:2005-2009年,第二阶段(P2):2010-2014年,以及时期3(P3):2015-2019.确定了总生存率和净生存率:与 P1 相比,P3 中确诊时年龄超过 60 岁的女性人数更多。I期女性比例仅略有增加(P1和P3分别为23.7%和27.2%,P = .004)。尽管如此,近来越来越多的患者表现为肿瘤较小、腋窝结节受累较少、肿瘤分化良好以及激素受体表达。人类表皮生长因子受体 2(HER2)表达肿瘤的女性比例明显下降。除了新辅助化疗和抗 HER2 治疗的用药量有所增加外,其他历时段内已确诊患者接受抗癌治疗的情况大致相同。15年间,患者的生存率显著提高,尤其是HER2暴露的BC患者:尽管我们观察到的 BC 存活率的提高证明了癌症控制工作和治疗方法的不断进步,但研究结果表明,在我们的环境中,还需要做更多的工作,以便更早地发现癌症,并更好地获得有效的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Trends in Presentation, Management, and Survival of Women With Breast Cancer in a Multiethnic, Middle-Income Asian Setting.

Purpose: Granular data on breast cancer (BC) are pertinent for surveillance, planning, and monitoring of cancer care delivery. We determined the trends in clinical presentation, management, and survival of women with BC in a multiethnic middle-income Asian setting over 15 years.

Methods: Data of 7,478 Malaysian women newly diagnosed with invasive BC between 2005 and 2019 from three hospital-based cancer registries were included. Trends in demographic, tumor, and treatment characteristics were compared across period 1 (P1): 2005-2009, period 2 (P2): 2010-2014, and period 3 (P3): 2015-2019. Overall survival and net survival were determined.

Results: More women in P3 than P1 were older than 60 years at diagnosis. Only a marginal increase in proportion of women with stage I disease was observed (23.7% v 27.2% in P1 and P3, respectively, P = .004). Nonetheless, patients were increasingly presenting with smaller tumors, fewer axillary node involvement, well-differentiated tumors, and hormone receptor expression in recent times. Proportion of women with human epidermal growth factor receptor 2 (HER2)-overexpressed tumors significantly decreased. Among indicated patients, receipt of anticancer therapies was somewhat similar over the calendar periods, except for neoadjuvant chemotherapy and anti-HER2 therapy, where increases in administration were noted. Significant improvements in survival were observed over the 15 years, particularly for HER2-overexpressed BCs.

Conclusion: Although the improvements in BC survival that we have observed validate ongoing cancer control efforts and treatment advances, study findings suggest that more could be done for earlier detection and improved access to effective therapies in our settings.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JCO Global Oncology
JCO Global Oncology Medicine-Oncology
CiteScore
6.70
自引率
6.70%
发文量
310
审稿时长
7 weeks
期刊最新文献
Intersectionality Between Country, Gender and Funding in Authorship for Phase III Trials Presented at the ASCO Annual Meeting 2022. Barriers to Follow-Up of an Abnormal Clinical Breast Examination in Uttar Pradesh, India: A Qualitative Study. Breast Cancer and Risk of Depression: A Comparative Cross-Sectional Study Among Women With and Without Breast Cancer in Addis Ababa, Ethiopia. Building an Effective International Medical Evacuation Program for Ukrainian Patients With Cancer Amid Prolonged Military Conflict. Clinical and Genomic Characterization of ERBB2-Altered Gallbladder Cancer: Exploring Differences Between an American and a Chilean Cohort.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1